Rajwinder Lehal

Rajwinder Lehal

Company: Cellestia Biotech

Job title: Chief Executive Officer


CSL as a Target for Inducing Immune Tolerance by Modulating Treg Cells & Application in Autoimmune Diseases 1:30 pm

CSL as a target for inducing immune tolerance by modulating Treg cells and application in autoimmune diseases Small molecule (CB-401/CB-433) mediated inhibition of CSL causes an expansion of Treg cells • CB-401/CB-433 induced Tregs maintain their suppressive characteristics Orally active CB-401/CB-433 alleviate autoimmune disease by re-establishing immune toleranceRead more

day: Day Two PM Non-Cell Based Approaches

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.